Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison

Data ReadoutpositiveFoundayooral semaglutidePositive

AI Analysis

Summary

Lilly's Foundayo 17.2 mg demonstrated superior weight loss and A1C reduction compared to oral semaglutide 25 mg in an indirect treatment comparison, building on positive head-to-head ACHIEVE-3 study results.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Foundayo 17.2 mg showed 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks in indirect treatment comparison; ACHIEVE-3 head-to-head study showed Foundayo 9 mg and 17.2 mg delivered greater A1C and weight reductions

Importance:6/10

Sentiment:

0.85

type 2 diabetesweight lossA1C reductioncomparative efficacyACHIEVE-3 trial

Related Companies

$LLY

Read the original article

Published by PR Newswire Biotech on September 29, 2026 7:00 AM

Read Original